Low Dose Naltrexone

Research Summary

Mechanism & Physiological Role

At sub-therapeutic doses, naltrexone transiently blocks opioid receptors, prompting compensatory upregulation of endogenous endorphin production and modulating microglial signaling.

Clinical & Research Applications

Studied in the literature on autoimmune conditions, inflammatory pain, and fibromyalgia. Prescribing decisions are made by the treating practitioner.

Biosynthesis, Handling & Sourcing

Naltrexone is a competitive opioid receptor antagonist that is commercially manufactured as an oral tablet at a single strength. Low-dose use means a strength no manufacturer produces, which is the whole reason a 503A pharmacy is involved: the preparation is compounded to a prescriber-specified strength for a named patient, rather than being a smaller package of an existing product. That distinction is worth keeping clear, because it is what places the preparation on the compounding pathway rather than the approved-product one.

Two separate pharmacologies are described in the literature and they are frequently conflated. The first is stereospecific and opioid: transient competitive blockade at the mu receptor, followed by compensatory changes in endogenous opioid signalling as the blockade clears. The second is not opioid at all and is attributed to the other enantiomer, which is described in the literature as an antagonist at Toll-like receptor 4 on microglia and is investigated in work on neuroinflammatory signalling. A page that presents only the first explanation is describing half of what has been studied.

Compounding considerations are mostly about content uniformity. A capsule at a small fraction of the manufactured strength contains very little active per unit, so the pharmacy is responsible for demonstrating that the active is distributed evenly through the powder blend rather than concentrated in some capsules and absent from others. These are non-sterile preparations compounded under USP General Chapter 795, and they carry a beyond-use date assigned at preparation. Practices should confirm the strength, the capsule count and the dating at account setup.

The evidence base should be described honestly. Systematic reviews in the peer-reviewed literature describe the human trials as small, heterogeneous in design and concentrated in a few indications, and they are consistent in calling for larger controlled work. Naltrexone is not FDA-approved at these strengths or for these uses, compounded medications are not FDA-approved finished drug products, and nothing on this page is a statement that any preparation is suitable for a given patient.